NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Scott H. Davis who wrote (583)	12/29/1999 12:49:00 AM
From: Mike McFarland	Read Replies (3) of 613

Probably Abgenix Xenomouse, could be Alexion. Also Medarex, see this Forbes article too: forbes.com Curagen has a deal with abgx for targets, or here is an older hit...could be Protein Design Laboratories, SMART. biotechnav.com That is thirty seconds of google for you <g> Here is a hit for HGSI and CAT hgsi.com This is for autoimmune disease? I guess cancer antigens and vaccines is a whole different line of questioning--here is where folks like myself start tripping over antibody versus antigen. Shame on me...well, it all leads back to genomics I suppose. What a shame I've muddled it all up in my head. Do you suppose part of the run-up in Curagen was due to the abgx deal--that was just for looking for targets for heavens sake, nobody said they had any yet. Plenty of ways to find targets, another tool leaps to mind, for cancer.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next